Europe Medical Aesthetics Market - 2023-2030
Market Overview
Europe medical aesthetics size was valued at US$ 3.8 billion in 2022 and is estimated to reach US$ 8.38 billion, growing at a CAGR of 10.4% during the forecast period (2023-2030).
Medical aesthetics is any medicine or medical procedure specializing in or intended to improve cosmetic appearance. A broad range of treatments and therapies are available from a medical aesthetician, including procedures that reduce, reverse, or otherwise minimize signs of aging, such as wrinkles, age spots, or loose and sagging skin.
Market Dynamics
The growing awareness regarding aesthetic procedures, rising adoption of minimally invasive procedures, technological advancement and increasing obese population are driving the Europe medical aesthetics market during the forecast period.
The growing rate of obesity in Europe regions and market developments are predicted to drive Europe’s market growth.
The growing rate of obesity in Europe regions and market developments are driving the market growth in the forecast period. For instance, according to the WHO, Europe region overweight and obesity affect almost 60% of adults. Being Overweight (including obesity) is a common problem affecting 4.4 million children under five years of age, representing 7.9% of all children in this age group. The WHO European Childhood Obesity Surveillance Initiative indicates that almost one in three school-aged children live overweight or obese. Prevalence decreases temporarily in adolescents, with one-quarter living overweight (including obesity). Alarmingly, there have been constant gains in the prevalence of obesity and overweight, and not a single Member State of the Region is on track to achieve the target of arresting the elevation in the obesity rate by 2025. Being chronically overweight and obese is one of the leading reasons for death and disability in Europe. Estimates propose they cause more than 1.2 million deaths annually, corresponding to more than 13% of total mortality in the region.
Again, in September 2020, Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, introduced the NuEra Tight with FocalRF technology in the Middle East and Europe. With this technology, body Sculpting takes on a new meaning as it offers a personalized solution for Skin Tightening, Fat Reduction, Wrinkle and Cellulite Reduction, all in one device. Also, Cynosure, a division of Hologic, introduced StimSure, a non-invasive electromagnetic technology to build and tone muscle in the abdomen, buttocks and thighs in Europe and the Middle East. This new addition to Cynosure's body portfolio joins SculpSure and TempSure to enable customers to offer a full-body solution. Thus, from the mentioned data, it is estimated that the growing obesity rate and market developments will drive market growth in the forecast period.
The side effects of medical aesthetic products are restraining the growth of Europe’s Medical Aesthetics market growth.
However, some medical aesthetics procedures are the safest and most popular but have some side effects used in these treatments. For instance, Mesotherapy, growing in demand, lacks scientific research, and standardized procedures lead to undocumented side effects like necrosis. Botox also reports ecchymosis (rashes) and edema (swelling), even if they are prevented with better procedures and user experience. These factors are limiting the market growth.
COVID-19 Impact
The appearance of COVID-19 considerably impacted the global medical aesthetics market. As per the article published in the Journal of Cosmetic Dermatology in June 2021, The COVID-19 pandemic has remarkably affected multiple aspects of life, among which it negatively impacted interest in medical aesthetics. Furthermore, lack of social communication during times of quarantines negatively influenced people's desire to seek cosmetic treatments. In addition, the aesthetic industry maintained its research and development practices in 2020 and 2021, despite uncertainties at the pandemic's start. The research was ongoing by the market players. For instance, in June 2020, Cynosure introduced the Elite iQ Aesthetic Workstation for laser skin revitalization and hair removal in the US, Europe, and Australia. Thus, providing a neutral impact on the market.
Segment Analysis
The skin tightening devices segment is expected to have a greater hold of Europe’s medical aesthetics market during the forecast period (2023-2030).
The skin tightening devices segment is expected to boost the market over the forecast period. To reduce fine lines and wrinkles, customers preferred skin tightening procedures. The advancement in skin-tightening devices drives the market. For instance, ultrasound (Ultherapy) is an FDA-approved skin-tightening technology that transfers micro-focused ultrasound energy deep into the lower layers of the skin to promote active collagen production. These skin-bypassing technologies can be effective with a wide range of patients, including those with darker skin color that may experience discoloration with a laser. It is mostly used to tighten the neck, jowls, chest, and brow areas, where the skin is a little thinner.
In addition, the market players are expanding their business to offer a strong portfolio in the market. For instance, in April 2021, Cynosure acquired the MyEllevate Surgical Suture System, expanding the Company's portfolio of minimally invasive facial rejuvenation solutions. This Acquisition will help to broaden Cynosure's extensive surgical product portfolio, enabling it to offer this ground-breaking procedure in combination with other energy-based skin-tightening technologies for optimal, long-lasting results. Also, in November 2020, Sofwave Medical, the emerging leader in energy-based non-invasive aesthetic medical devices, received CE Mark (Conformité Européenne) for its next-generation Sofwave system was authorized for use in the treatment of fine lines and wrinkles in the EU. Furthermore, the increasing research on skin-tightening devices ensures the dominance of the segment on the market. For instance, according to the Official Publication of the American Society for Dermatologic Surgery, published article conclusion, the Radiofrequency fractional micro-needling (RFMN) treatment is a safe and effective technique for rejuvenation of the lower face, jawline, and neck region. Thus, from the data mentioned, it is estimated that the skin-tightening devices segment will dominate the market throughout the forecast period.
Geographical Analysis
Germany is expected to dominate the Europe medical aesthetics market.
In Germany, lower fertility and growing life expectancy have resulted in a rapidly aging population. Presently, the median age of German residents is 46 years, nearly four years more than the median age of the adjacent country of France, making Germany one of the oldest countries worldwide. Again, according to the OECD, ilibrary the median age in Germany is expected to rise from 45.7 years in 2020 to 49.2 years by 2045. Thus, while Germany is already a rather old country, its population is aging fast. Moreover, according to the World Bank collection of development indicators population ages 65 and above (% of the total population) in Germany was reported at 22.17 % in 2021.
Additionally, according to the Statistisches Bundesamt (Destatis) estimation, the number of people at retirement age (67 years or over) in Germany will rise by roughly 4 million to at least 20.0 million by the middle of the 2030s. The number of those aged 80 or over will remain relatively stable until the middle of the 2030s, amounting to between 5.8 and 6.7 million. Furthermore, according to the Robert Koch Institute, a Federal Institute within the Federal Ministry of Health's portfolio, two-thirds of men (67%) and half of the women (53%) in Germany are overweight. A quarter of adults (23% of men and 24% of women) are seriously overweight (obese). Thus, the growing geriatric and obese population will ensure the dominance of Germany in the market throughout the forecast period.
Competitive Landscape
The Europe medical aesthetics market is competitive due to the increasing demand ket developments of new market players. The key players operating in the Europe Medical Aesthetics market hold most of the market share examples: Abbvie Inc. (Allergan Inc.), Lumenis Inc., Johnson and Johnson, Cutera Inc, Alma Lasers, Syneron Medical Ltd, Asclepion Laser Technologies Gmbh, Merz Pharma, El.En. S.p.A, and Galderma Pharmaceuticals, among others. The key players are embracing various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the European Medical Aesthetics market. For instance, in May 2020, US Food and Drug Administration (FDA) approved Galderma's for its Restylane Kysse for lip augmentation and the correction of upper perioral rhytids (wrinkles around upper lips) in adults over the age of 21.
Merz Pharma
Overview:
Merz is a family-owned company that has its business spread globally. Merz has business in Germany, Europe, Asia Pacific, the Middle East, Latin America and North America. It has been involved in the innovation and production of aesthetics and therapeutics and providing consumer help for over 110 years. Merz Pharma GmbH & Co. is a parent company with subsidiaries such as asteis SA, Merz North America Inc., Merz Pharma GmbH, Merz pharma France and Merz Pharma (Schweiz) Ag.
Product Portfolio
The Company’s portfolio has Ultherapy: It is an FDA-approved, non-invasive procedure that improves lines and wrinkles in the upper chest by lifting the neck, chin and brow. It works through ultrasound energy directed at a precise location where the result is expected.
Europe medical aesthetics report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook